Studies have shown that high expression of PD-1 on peripheral blood CD4+ T cells in NSCLC patients receiving anti-PD-L1 therapy is associated with adverse clinical outcomes. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.